Analytica Limited designs, develops, and supplies medical devices in Australia, China, and the Middle East.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.002|
|52 Week High||AU$0.001|
|52 Week Low||AU$0.006|
|1 Month Change||0%|
|3 Month Change||-20.00%|
|1 Year Change||-20.00%|
|3 Year Change||-66.67%|
|5 Year Change||-77.78%|
|Change since IPO||-99.95%|
Recent News & Updates
Does Analytica's (ASX:ALT) CEO Salary Compare Well With The Performance Of The Company?
Geoff Daly has been the CEO of Analytica Limited ( ASX:ALT ) since 2014, and this article will examine the executive's...
|ALT||AU Medical Equipment||AU Market|
Return vs Industry: ALT underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: ALT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: ALT is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 19% a week.
Volatility Over Time: ALT's weekly volatility has decreased from 36% to 19% over the past year, but is still higher than 75% of Australian stocks.
About the Company
Analytica Limited designs, develops, and supplies medical devices in Australia, China, and the Middle East. The company’s lead product is PeriCoach system, an e-health treatment system for women used in treatment of stress urinary incontinence. Its PeriCoach comprises a device, Web portal, and smartphone app for evaluating activity in pelvic floor muscles.
Analytica Fundamentals Summary
|ALT fundamental statistics|
Is ALT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALT income statement (TTM)|
|Cost of Revenue||AU$1.12m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.00032|
|Net Profit Margin||-188.09%|
How did ALT perform over the long term?See historical performance and comparison
Is Analytica undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALT is good value based on its PB Ratio (4.4x) compared to the AU Medical Equipment industry average (5x).
How is Analytica forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Analytica has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Analytica performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, but has reduced losses over the past 5 years at a rate of 23.7% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: ALT has a negative Return on Equity (-72.06%), as it is currently unprofitable.
How is Analytica's financial position?
Financial Position Analysis
Short Term Liabilities: ALT's short term assets (A$2.2M) exceed its short term liabilities (A$505.5K).
Long Term Liabilities: ALT's short term assets (A$2.2M) exceed its long term liabilities (A$11.3K).
Debt to Equity History and Analysis
Debt Level: ALT is debt free.
Reducing Debt: ALT had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALT has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 23% each year.
What is Analytica current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Geoff Daly, BE (Hons, Mech, UQ), MBA (Exec, AGSM), MIEAust CPEng (Mech, Biomed), MAICD has been the Chief Executive Officer of Analytica Ltd. since February 12, 2014. Mr. Daly served as the Chief Opera...
CEO Compensation Analysis
Compensation vs Market: Geoff's total compensation ($USD211.50K) is about average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Geoff's compensation has increased whilst the company is unprofitable.
Experienced Board: ALT's board of directors are seasoned and experienced ( 13 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.1%.
Analytica Limited's employee growth, exchange listings and data sources
- Name: Analytica Limited
- Ticker: ALT
- Exchange: ASX
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$9.228m
- Shares outstanding: 4.61b
- Website: https://www.analyticamedical.com
Number of Employees
- Analytica Limited
- 320 Adelaide Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:20|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.